SAVVY Vaginal Gel for Preventing HIV Infection
Author Information
Author(s): Feldblum Paul J., Adeiga Adesina, Bakare Rashidi, Wevill Silver, Lendvay Anja, Obadaki Fatimah, Olayemi M. Onikepe, Wang Lily, Nanda Kavita, Rountree Wes
Primary Institution: Family Health International, Research Triangle Park, North Carolina, United States
Hypothesis
The trial aimed to determine the effectiveness of 1.0% C31G (SAVVY) in preventing male-to-female vaginal transmission of HIV infection among women at high risk.
Conclusion
SAVVY did not reduce the incidence of HIV infection among participants.
Supporting Evidence
- 33 seroconversions were observed, with 21 in the SAVVY group and 12 in the placebo group.
- The cumulative probability of HIV infection at 12 months was 0.028 in the SAVVY group and 0.015 in the placebo group.
- The hazard ratio for SAVVY versus placebo was 1.7.
- Adverse events were similar in both groups, with no serious adverse events attributable to SAVVY use.
- Follow-up loss to follow-up was approximately 23%.
Takeaway
The study tested a gel to see if it could help prevent HIV in women, but it didn't work as hoped.
Methodology
This was a Phase 3, double-blind, randomized, placebo-controlled trial with 2153 HIV-negative women at high risk of HIV infection.
Potential Biases
Participants may have reported higher adherence to gel use than actually occurred.
Limitations
The study was terminated early due to lower-than-expected HIV incidence, which limited the power to detect an effect.
Participant Demographics
Participants were HIV-negative women aged 18-35, primarily unmarried and with more than 9 years of education.
Statistical Information
P-Value
0.121
Confidence Interval
0.9, 3.5
Statistical Significance
p=0.121
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website